G1's trilaciclib leads to PFS of up to 8.8 months in Phase II for TNBC

G1 Therapeutics Inc. (NASDAQ:GTHX) said trilaciclib (G1T28) administered on the day of chemotherapy led to a preliminary median progression-free survival (PFS) of 8.8 months vs. 5.4 months for chemotherapy alone in a Phase II trial to treat metastatic triple-negative breast cancer (TNBC) (HR=0.52, p=0.0669). Trilaciclib administered the day prior to and on the day of chemotherapy led to a preliminary median PFS of 7.3 months (HR=0.49, p=0.0546).

Preliminary objective response rates (ORRs) for the respective trilaciclib regimens were 43.3% and 36.7% vs. 29.2% for chemotherapy alone. Overall survival (OS) data are not yet mature. Data were presented at the San Antonio Breast Cancer Symposium...